source
- Axiom Biosciences targets Hong Kong IPO to raise up to $200 million for regenerative therapy pipelineAxiom Biosciences, a San Diego‑based biotech, announced plans to list on the Hong Kong Stock Exchange rather than the traditional U.S. exchanges. The company aims to use the offering to secure new…
- Eli Lilly’s $3.8 B bid for AtaiBeckley signals strong pharma endorsement of psychedelicsEli Lilly has announced a proposed acquisition of AtaiBeckley valued at up to $3.8 billion. Analysts at H.C. Wainwright described the move as the clearest strategic validation to date of psychedeli…